← All trials
NCT06465485
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2024
- Primary completion
- Oct 31, 2025
- Completion date
- Aug 31, 2026
- First posted
- Jun 18, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 500
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Zhejiang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.